1887

Abstract

Daptomycin and levofloxacin were tested as monotherapies and in combination against the antibiotic-susceptible strain MSSA 1112 in a rabbit meningitis model and the effect of the combination on induction of resistance was determined .

Treatment combination might be more efficacious than the monotherapies regarding antibacterial efficacy and development of resistance.

To demonstrate a synergy of the antibiotic combination daptomycin and levofloxacin in experimental meningitis, and also its ability to reduce the emergence of resistance against the antibiotics .

Changes of the susceptibility to fluoroquinolones and daptomycin were determined by the measurement of the MIC and mutations were detected by whole genome sequence comparison of the mutants with the parent strain MSSA 1112. Meningitis was induced by intracisternal inoculation of 10 c.f.u. (colony forming unit) of MSSA 1112 and treatment was started 10 h later by injection of daptomycin (15 mg kg) and levofloxacin (10 mg kg) standard doses. Cerebrospinal fluid (CSF) samples were repeatedly collected during therapy in order to determine killing rates and results of bactericidal activity were expressed in Δlogc.f.u. ml over 8 h.

The combination of daptomycin with levofloxacin was significantly (<0.001) superior to levofloxacin monotherapy and increased the antibacterial activity of daptomycin. , MSSA 1112 was cycled over 6 days with either increasing concentrations of levofloxacin or daptomycin or with a combination of levofloxacin with half of the MIC of daptomycin or daptomycin with half of the MIC of levofloxacin leading to mutations in target genes as identified by whole genome sequence analysis. Addition of low concentration of daptomycin (0.25 mg l) reduced levofloxacin-induced resistance . Addition of levofloxacin in low concentration (0.125 mg l) did not influence daptomycin-induced resistance.

These findings highlight the lack of reciprocal interference of antibiotics in combination with regard to the development of resistance.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001497
2022-02-02
2024-03-29
Loading full text...

Full text loading...

References

  1. Aguilar J, Urday-Cornejo V, Donabedian S, Perri M, Tibbetts R et al. Staphylococcus aureus Meningitis. Medicine 2010; 89:117–125 [View Article] [PubMed]
    [Google Scholar]
  2. John J. The treatment of resistant staphylococcal infections. F1000Res 2020; 9:F1000 Faculty Rev-150 [View Article] [PubMed]
    [Google Scholar]
  3. Flatz L, Cottagnoud M, Kühn F, Entenza J, Stucki A et al. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. J Antimicrob Chemother 2004; 53:305–310 [View Article] [PubMed]
    [Google Scholar]
  4. Gerber P, Stucki A, Acosta F, Cottagnoud M, Cottagnoud P. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006; 57:720–723 [View Article] [PubMed]
    [Google Scholar]
  5. Sabat AJ, Tinelli M, Grundmann H, Akkerboom V, Monaco M et al. Daptomycin resistant Staphylococcus aureus clinical strain with novel non-synonymous mutations in the mprF and vraS genes: a new insight into daptomycin resistance. Front Microbiol 2018; 9:2705 [View Article]
    [Google Scholar]
  6. Kashyap R, Shah A, Dutt T, Wieruszewski PM, Ahdal J et al. Treatments and limitations for methicillin-resistant Staphylococcus aureus: A review of current literature. WJCID 2019; 9:1–10 [View Article]
    [Google Scholar]
  7. Fuzi M, Rodriguez Baño J, Toth A. Global evolution of pathogenic bacteria with extensive use of fluoroquinolone agents. Front Microbiol 2020; 11:271 [View Article] [PubMed]
    [Google Scholar]
  8. Hooper DC, Jacoby GA. Topoisomerase Inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med 2016; 6:a025320 [View Article] [PubMed]
    [Google Scholar]
  9. Ernst CM, Peschel A. MprF-mediated daptomycin resistance. Int J Med Microbiol 2019; 309:359–363 [View Article] [PubMed]
    [Google Scholar]
  10. Gómez Casanova N, Siller Ruiz M, Muñoz Bellido JL. Mechanisms of resistance to daptomycin in Staphylococcus aureus. Rev Esp Quimioter 2017; 30:391–396 [PubMed]
    [Google Scholar]
  11. Barros EM, Martin MJ, Selleck EM, Lebreton F, Sampaio JLM et al. Daptomycin resistance and tolerance due to loss of function in sstaphylococcus aureus dsp1 and asp23. Antimicrob Agents Chemother 2019; 63:e01542-18 [View Article]
    [Google Scholar]
  12. Miller WR, Bayer AS, Arias CA. Mechanism of action and resistance to daptomycin in Staphylococcus aureus and enterococci. Cold Spring Harb Perspect Med 2016; 6:a026997 [View Article] [PubMed]
    [Google Scholar]
  13. Coe KA, Lee W, Stone MC, Komazin-Meredith G, Meredith TC et al. Multi-strain Tn-Seq reveals common daptomycin resistance determinants in Staphylococcus aureus. PLoS Pathog 2019; 15:e1007862 [View Article] [PubMed]
    [Google Scholar]
  14. Blake KL, O’Neill AJ. Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. J Antimicrob Chemother 2013; 68:12–16 [View Article] [PubMed]
    [Google Scholar]
  15. Kühn F, Cottagnoud M, Acosta F, Flatz L, Entenza J et al. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob Agents Chemother 2003; 47:2487–2491 [View Article] [PubMed]
    [Google Scholar]
  16. Dacey RG, Sande MA. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974; 6:437–441 [View Article] [PubMed]
    [Google Scholar]
  17. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41:1662–1667 [View Article] [PubMed]
    [Google Scholar]
  18. Wu SS, Wang W, Annis DH. On identification of the number of best treatments using the Newman-Keuls test. Biom J 2008; 50:861–869 [View Article] [PubMed]
    [Google Scholar]
  19. CLSI Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed. CLSI standard M07. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
    [Google Scholar]
  20. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014; 30:2114–2120 [View Article] [PubMed]
    [Google Scholar]
  21. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 2017; 13:e1005595 [View Article] [PubMed]
    [Google Scholar]
  22. Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res 2016; 44:6614–6624 [View Article] [PubMed]
    [Google Scholar]
  23. Cottagnoud P, Cottagnoud M, Acosta F, Flatz L, Kühn F et al. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur J Clin Microbiol Infect Dis 2003; 22:656–662 [View Article] [PubMed]
    [Google Scholar]
  24. Cottagnoud P, Pfister M, Acosta F, Cottagnoud M, Flatz L et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928–3933 [View Article] [PubMed]
    [Google Scholar]
  25. Egermann U, Stanga Z, Ramin A, Acosta F, Stucki A et al. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob Agents Chemother 2009; 53:3030–3033 [View Article] [PubMed]
    [Google Scholar]
  26. Scotton PG, Pea F, Giobbia M, Baraldo M, Vaglia A et al. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clin Infect Dis 2001; 33:e109–11 [View Article] [PubMed]
    [Google Scholar]
  27. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002; 46:31–33 [View Article] [PubMed]
    [Google Scholar]
  28. Lasek-Nesselquist E, Lu J, Schneider R, Ma Z, Russo V et al. Insights into the evoInto the Evolution of Staphylococcus aureus daptomycin resistance from an in vitro bioreactor moDaptomycin Resistance From an in vitro Bioreactor Model. Front Microbiol 2019; 10:345 [View Article]
    [Google Scholar]
  29. Schmitz F-J, Köhrer K, Scheuring S, Verhoef J, Fluit A et al. The stability of grlA, grlB, gyrA, gyrB and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 1999; 5:287–290 [View Article] [PubMed]
    [Google Scholar]
  30. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9:617–624 [View Article] [PubMed]
    [Google Scholar]
  31. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42:1652–1653 [View Article] [PubMed]
    [Google Scholar]
  32. Lee CH, Wang MC, Huang IW, Chen FJ, Lauderdale TL. Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment. Antimicrob Agents Chemother 2010; 54:4038–4040 [View Article] [PubMed]
    [Google Scholar]
  33. Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66:1057–1060 [View Article] [PubMed]
    [Google Scholar]
  34. Chen F-J, Lauderdale T-L, Lee C-H, Hsu Y-C, Huang I-W et al. Effect of a point mutation in mprf on susceptibility to daptomycin, vancomycin, and oxacillsusceptibility to daptomycin, vancomycin, and oxacillin in an mrsa clinical stclinical strain. Front Microbiol 2018; 9:9–1086 [View Article]
    [Google Scholar]
  35. Thitiananpakorn K, Aiba Y, Tan XE, Watanabe S, Kiga K et al. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA). Sci Rep 2020; 10:16107 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001497
Loading
/content/journal/jmm/10.1099/jmm.0.001497
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error